Stock performance snapshot after recent trading move
Sherwin-Williams (SHW) has drawn investor interest after its latest trading session, with the stock closing at $317.30. Recent returns show mixed momentum, including gains over the past week and month and declines over the year to date and past year.
See our latest analysis for Sherwin-Williams.
Recent trading has been slightly positive at the share price level, with a 7 day share price return of 3.93% and a 30 day share price return of 3.58%. This sits against weaker momentum over the year to date and a 1 year total shareholder return that declined 4.65%. However, the 3 year and 5 year total shareholder returns of 31.44% and 23.76% point to a more resilient longer term record.
If this kind of mixed performance has you thinking about other opportunities in the market, it could be a good moment to scan for 20 top founder-led companies
With Sherwin-Williams trading at $317.30 and data pointing to both an intrinsic discount and a discount to analyst targets, the real question is whether you are looking at a genuine value opportunity or at a stock where the market is already pricing in future growth.
Most Popular Narrative: 18.3% Undervalued
The most followed narrative puts Sherwin-Williams' fair value at $388.14, comfortably above the last close at $317.30. This raises clear questions about what is embedded in those assumptions.
The company's sustained focus on cost control, broad and deep restructuring (doubling annual savings targets to ~$80 million), and disciplined SG&A management is structurally improving fixed cost leverage and expected to yield improved net margins and earnings power as sales volumes recover.
Want to see what sits behind that earnings power claim? The narrative references steady revenue gains, firmer margins, and a premium future earnings multiple. The exact mix of those ingredients is what really drives the $388.14 fair value.
Result: Fair Value of $388.14 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative can be knocked off course if weak demand in key end markets persists or if supply chain inefficiencies continue to pressure margins and earnings.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Another View: Rich Earnings Multiple Puts Pressure On The Story
The fair value narrative leans on discounted cash flows, but the current P/E of 29.9x sits above both the US Chemicals industry at 28.1x and the peer average at 24.3x, and above a fair ratio of 24x. That gap suggests investors are already paying up, so how much margin for error is really left?
To see what the numbers say about this pricing and how it could shift if sentiment cools, take a look at the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals in this story, you may wish to review the numbers yourself and see how they compare with your expectations by checking the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Sherwin-Williams has sharpened your thinking, do not stop here. Use the Simply Wall Street Screener to explore other opportunities.
- Target potential mispriced opportunities by reviewing companies in the 44 high quality undervalued stocks that combine quality with discounted share prices.
- Prioritize resilience by scanning stocks in the 70 resilient stocks with low risk scores where business fundamentals and measured risk scores work together.
- Identify possible future leaders by checking the screener containing 20 high quality undiscovered gems that have strong fundamentals but limited market attention so far.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com